Gritstone Bio Analyst Ratings
Gritstone Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2022 | 165.15% | HC Wainwright & Co. | $12 → $7 | Maintains | Buy |
| 10/31/2022 | 127.27% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 08/22/2022 | -24.24% | Goldman Sachs | → $2 | Downgrades | Neutral → Sell |
| 05/09/2022 | 354.55% | HC Wainwright & Co. | $15 → $12 | Maintains | Buy |
| 03/14/2022 | 468.18% | HC Wainwright & Co. | $24 → $15 | Maintains | Buy |
| 01/20/2021 | 203.03% | Baird | → $8 | Downgrades | Outperform → Underperform |
| 01/20/2021 | 809.09% | HC Wainwright & Co. | $16 → $24 | Maintains | Buy |
| 07/14/2020 | 543.94% | BTIG | $31 → $17 | Maintains | Buy |
| 07/26/2019 | 543.94% | Baird | → $17 | Initiates Coverage On | → Outperform |
| 03/15/2019 | 657.58% | Raymond James | → $20 | Initiates Coverage On | → Outperform |
| 03/07/2019 | 543.94% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 10/23/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 10/23/2018 | 581.82% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 10/23/2018 | 884.85% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 10/23/2018 | 846.97% | Barclays | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析师公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 7 月 11 日 | 165.15% | HC Wainwright & Co. | 12 美元 → 7 美元 | 维护 | 买 |
| 10/31/2022 | 127.27% | 派珀·桑德勒 | → 6 美元 | 启动覆盖范围开启 | → 超重 |
| 2022 年 8 月 22 日 | -24.24% | 高盛 | → 2 美元 | 降级 | 中立 → 卖出 |
| 05/09/2022 | 354.55% | HC Wainwright & Co. | 15 美元 → 12 美元 | 维护 | 买 |
| 03/14/2022 | 468.18% | HC Wainwright & Co. | 24 美元 → 15 美元 | 维护 | 买 |
| 2021 年 1 月 20 日 | 203.03% | 贝尔德 | → 8 美元 | 降级 | 跑赢大盘 → 表现不佳 |
| 2021 年 1 月 20 日 | 809.09% | HC Wainwright & Co. | 16 美元 → 24 美元 | 维护 | 买 |
| 2020 年 7 月 14 日 | 543.94% | BTIG | 31 美元 → 17 美元 | 维护 | 买 |
| 07/26/2019 | 543.94% | 贝尔德 | → 17 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 03/15/2019 | 657.58% | 雷蒙德·詹姆 | → 20 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2019 年 7 月 3 日 | 543.94% | HC Wainwright & Co. | → 17 美元 | 启动覆盖范围开启 | → 购买 |
| 10/23/2018 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 10/23/2018 | 581.82% | 高盛 | → 18 美元 | 启动覆盖范围开启 | → 中立 |
| 10/23/2018 | 884.85% | BTIG | → 26 美元 | 启动覆盖范围开启 | → 购买 |
| 10/23/2018 | 846.97% | 巴克莱 | → 25 美元 | 启动覆盖范围开启 | → 超重 |
Gritstone Bio Questions & Answers
Gritstone 生物问答
The latest price target for Gritstone Bio (NASDAQ: GRTS) was reported by HC Wainwright & Co. on November 7, 2022. The analyst firm set a price target for $7.00 expecting GRTS to rise to within 12 months (a possible 165.15% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年11月7日公布了Gritstone Bio（纳斯达克股票代码：GRTS）的最新目标股价。该分析公司将目标股价定为7.00美元，预计GRTS将在12个月内升至12个月内（可能上涨165.15％）。去年有5家分析公司公布了评级。
The latest analyst rating for Gritstone Bio (NASDAQ: GRTS) was provided by HC Wainwright & Co., and Gritstone Bio maintained their buy rating.
HC Wainwright & Co. 对Gritstone Bio（纳斯达克股票代码：GRTS）的最新分析师评级由HC Wainwright & Co. 提供，Gritstone Bio维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gritstone Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gritstone Bio was filed on November 7, 2022 so you should expect the next rating to be made available sometime around November 7, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Gritstone Bio的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Gritstone Bio的最新评级是在2022年11月7日发布的，因此您应该预计下一个评级将在2023年11月7日左右公布。
While ratings are subjective and will change, the latest Gritstone Bio (GRTS) rating was a maintained with a price target of $12.00 to $7.00. The current price Gritstone Bio (GRTS) is trading at is $2.64, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Gritstone Bio（GRTS）评级保持不变，目标股价为12.00美元至7.00美元。Gritstone Bio（GRTS）目前的交易价格为2.64美元，超出了分析师的预期区间。
译文内容由第三方软件翻译。